Cover Image
市場調查報告書

tau蛋白病變:開發中產品分析

Tauopathies - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 293886
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
tau蛋白病變:開發中產品分析 Tauopathies - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 54 Pages
簡介

tau蛋白病變是由於tau蛋白的異常沈積所引發的神經病變。常見的症狀有人格·社會行動·語言能力的變化、思考·決策障礙、協調運動不全·平衡障礙、精神科症狀和癡呆症等。

本報告提供tau蛋白病變的治療藥開發情形調查分析,提供您開發中的產品概要,臨床實驗各階段的產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

tau蛋白病變概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Selvita S.A
  • SK Biopharmaceuticals Co., Ltd.
  • Chronos Therapeutics Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Monoclonal Antibody Targeting TAU Protein for Alzheimers Disease
  • SEL-141
  • RDC-5
  • Gene Therapy for Tauopathies
  • YM-08
  • Thiamet-G
  • Enantiomeric Diarylheptanoid
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders
  • Small Molecule for Tauopathies and Alzheimers Disease
  • Monoclonal Antibodies Targeting Tau Protein
  • Small Molecules to Inhibit Microtubule Affinity Regulating Kinase for Neurodegenerative Diseases
  • Small Molecule for Alzheimer's Disease and Tauopathies

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7355IDB

Summary

Global Markets Direct's, 'Tauopathies - Pipeline Review, H2 2015', provides an overview of the Tauopathies's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tauopathies, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tauopathies and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Tauopathies
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Tauopathies and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Tauopathies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Tauopathies pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Tauopathies
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Tauopathies pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Tauopathies Overview
  • Therapeutics Development
    • Pipeline Products for Tauopathies - Overview
    • Pipeline Products for Tauopathies - Comparative Analysis
  • Tauopathies - Therapeutics under Development by Companies
  • Tauopathies - Therapeutics under Investigation by Universities/Institutes
  • Tauopathies - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Tauopathies - Products under Development by Companies
  • Tauopathies - Products under Investigation by Universities/Institutes
  • Tauopathies - Companies Involved in Therapeutics Development
    • Bristol-Myers Squibb Company
    • Chronos Therapeutics Limited
    • Prothena Corporation Plc
    • Selvita SA
    • SK Biopharmaceuticals Co., Ltd.
    • Summit Therapeutics Plc
  • Tauopathies - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies to Inhibit Tau Protein for Alzheimer's Disease and Tauopathies - Drug Profile Product Description
      • Mechanism of Action
      • R&D Progress
    • BMS-986168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Tauopathies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GTC-6000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RDC-5 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SEL-141 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Tauopathies and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Alzheimer's Disease and Tauopathies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Tau for Alzheimer Disease and Tauopathies - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Thiamet-G - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine to Target Tau for Alzheimer's Disease and Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YM-08 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tauopathies - Recent Pipeline Updates
  • Tauopathies - Dormant Projects
  • Tauopathies - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2013: Summit Reports New Data From OGA Inhibitor Program For Treatment Of Tauopathies
      • Aug 02, 2012: Summit Receives £150,000 Grant From Biomedical Catalyst
      • Jul 17, 2012: Summit Presents New Data On OGA Inhibition At Alzheimer's Association International Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Tauopathies, H2 2015
  • Number of Products under Development for Tauopathies - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Tauopathies - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Tauopathies - Pipeline by Chronos Therapeutics Limited, H2 2015
  • Tauopathies - Pipeline by Prothena Corporation Plc, H2 2015
  • Tauopathies - Pipeline by Selvita SA, H2 2015
  • Tauopathies - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
  • Tauopathies - Pipeline by Summit Therapeutics Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Tauopathies Therapeutics - Recent Pipeline Updates, H2 2015
  • Tauopathies - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Tauopathies, H2 2015
  • Number of Products under Development for Tauopathies - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top